These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 26555126)

  • 1. Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients.
    Lubitz CC; Economopoulos KP; Sy S; Johanson C; Kunzel HE; Reincke M; Gazelle GS; Weinstein MC; Gaziano TA
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):621-30. PubMed ID: 26555126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and diagnosis of primary aldosteronism.
    Rossi GP
    Curr Hypertens Rep; 2010 Oct; 12(5):342-8. PubMed ID: 20665130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomised diagnostic trial.
    Dekkers T; Prejbisz A; Kool LJS; Groenewoud HJMM; Velema M; Spiering W; Kołodziejczyk-Kruk S; Arntz M; Kądziela J; Langenhuijsen JF; Kerstens MN; van den Meiracker AH; van den Born BJ; Sweep FCGJ; Hermus ARMM; Januszewicz A; Ligthart-Naber AF; Makai P; van der Wilt GJ; Lenders JWM; Deinum J;
    Lancet Diabetes Endocrinol; 2016 Sep; 4(9):739-746. PubMed ID: 27325147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.
    Gu D; He J; Coxson PG; Rasmussen PW; Huang C; Thanataveerat A; Tzong KY; Xiong J; Wang M; Zhao D; Goldman L; Moran AE
    PLoS Med; 2015 Aug; 12(8):e1001860. PubMed ID: 26241895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of adrenal vein sampling- vs computed tomography-guided adrenalectomy for unilateral adrenaloma in primary aldosteronism.
    Arjani S; Bostonian TJ; Prasath V; Quinn PL; Chokshi RJ
    J Endocrinol Invest; 2022 Oct; 45(10):1899-1908. PubMed ID: 35612811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telemonitoring and self-management in the control of hypertension (TASMINH2): a cost-effectiveness analysis.
    Kaambwa B; Bryan S; Jowett S; Mant J; Bray EP; Hobbs FD; Holder R; Jones MI; Little P; Williams B; McManus RJ
    Eur J Prev Cardiol; 2014 Dec; 21(12):1517-30. PubMed ID: 23990660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and management of primary aldosteronism.
    Vilela LAP; Almeida MQ
    Arch Endocrinol Metab; 2017; 61(3):305-312. PubMed ID: 28699986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Adrenal Vein Sampling Use and Outcomes in Patients With Primary Aldosteronism.
    Yeung A; Friedmann P; In H; Bloomgarden N; McAuliffe JC; Libutti SK; Laird AM
    J Surg Res; 2020 Dec; 256():673-679. PubMed ID: 32827833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for primary aldosteronism in the hypertensive obstructive sleep apnea population is cost-saving.
    Chomsky-Higgins Menut K; Pearlstein SS; Conroy PC; Roman SA; Shen WT; Gosnell J; Sosa JA; Duh QY; Suh I
    Surgery; 2022 Jan; 171(1):96-103. PubMed ID: 34238603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of self-management of blood pressure in hypertensive patients over 70 years with suboptimal control and established cardiovascular disease or additional cardiovascular risk diseases (TASMIN-SR).
    Penaloza-Ramos MC; Jowett S; Mant J; Schwartz C; Bray EP; Sayeed Haque M; Richard Hobbs FD; Little P; Bryan S; Williams B; McManus RJ
    Eur J Prev Cardiol; 2016 Jun; 23(9):902-12. PubMed ID: 26603745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should all Hypertensive Patients be Screened for Primary Aldosteronism?
    Alkagiet S; Tziomalos K
    Curr Hypertens Rev; 2019; 15(1):54-56. PubMed ID: 29737255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of the Diagnosis and Treatment of Primary Aldosteronism in Japan.
    Sato M; Morimoto R; Seiji K; Iwakura Y; Ono Y; Kudo M; Satoh F; Ito S; Ishibashi T; Takase K
    Horm Metab Res; 2015 Oct; 47(11):826-32. PubMed ID: 26305168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Therapeutic Drug Monitoring in Diagnosing Primary Aldosteronism in Patients With Resistant Hypertension.
    Velasco A; Chung O; Raza F; Pandey A; Brinker S; Arbique D; Price A; Lotan Y; Das SR; Vongpatanasin W
    J Clin Hypertens (Greenwich); 2015 Sep; 17(9):713-9. PubMed ID: 25917401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of screening for primary aldosteronism in China.
    Li N; Huang J; Zheng B; Cai H; Liu M; Liu L
    Clin Endocrinol (Oxf); 2021 Sep; 95(3):414-422. PubMed ID: 33837588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.
    Moise N; Huang C; Rodgers A; Kohli-Lynch CN; Tzong KY; Coxson PG; Bibbins-Domingo K; Goldman L; Moran AE
    Hypertension; 2016 Jul; 68(1):88-96. PubMed ID: 27181996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission.
    Huntington SF; Svoboda J; Doshi JA
    J Clin Oncol; 2015 May; 33(13):1467-74. PubMed ID: 25823735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control.
    Bress AP; Bellows BK; King JB; Hess R; Beddhu S; Zhang Z; Berlowitz DR; Conroy MB; Fine L; Oparil S; Morisky DE; Kazis LE; Ruiz-Negrón N; Powell J; Tamariz L; Whittle J; Wright JT; Supiano MA; Cheung AK; Weintraub WS; Moran AE;
    N Engl J Med; 2017 Aug; 377(8):745-755. PubMed ID: 28834469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary Aldosteronism: Present and Future.
    Funder JW
    Vitam Horm; 2019; 109():285-302. PubMed ID: 30678860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis.
    Montgomery AA; Fahey T; Ben-Shlomo Y; Harding J
    J Hypertens; 2003 Sep; 21(9):1753-9. PubMed ID: 12923409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of screening for primary aldosteronism in hypertensive patients in Australia: a Markov modelling analysis.
    Woode ME; Wong K; Reid CM; Stowasser M; Russell G; Gwini S; Young MJ; Fuller PJ; Yang J; Chen G
    J Hypertens; 2023 Oct; 41(10):1615-1625. PubMed ID: 37466447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.